Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups A, B, C, W, and Y vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pentavalent meningococcal vaccine (MenABCWY) designed to provide broad protection against the five most common serogroups of Neisseria meningitidis (A, B, C, W, and Y). These vaccines combine the components of a quadrivalent meningococcal conjugate vaccine (MenACWY) with a meningococcal group B vaccine (MenB). Pfizer's Penbraya combines the components of Trumenba (MenB) and Nimenrix (MenACWY-TT). GSK's Penmenvy combines components from Bexsero (MenB) and Menveo (MenACWY-CRM). They are administered as an intramuscular injection to prevent invasive meningococcal disease, including meningitis and septicemia, by inducing bactericidal antibodies against bacterial surface antigens.
- Brand names
- PenbrayaPenmenvy
- Other names
- MenABCWY vaccinepentavalent meningococcal vaccinemeningococcal group B vaccine + meningococcal conjugate vaccine
02
Targets
PorAHS (Heparan sulfate)NadA (Neisserial adhesin A)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NHBA (Neisserial heparin-binding antigen)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)fHbp (Factor H-binding protein)CFH (Complement factor H)
Beyond the preview
Go deeper on meningococcal groups A, B, C, W, and Y vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups A, B, C, W, and Y vaccine.